11/25/2022  5:31:15 PM Chg. +0.0004 Volume Bid8:11:52 PM Ask8:11:52 PM Market Capitalization Dividend Y. P/E Ratio
0.0300CHF +1.35% 5.04 mill.
Turnover: 151,686.7783
0.0340Bid Size: 50,000 -Ask Size: 25,000 132.4 mill.CHF - -

Business description

RELIEF THERAPEUTICS Holding AG was formed in June 2016 following the merger of Relief Therapeutics SA and THERAMetrics Holding AG. RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company with a portfolio of drug candidates derived from natural human origins. Its two most promising drug candidates are Aviptadil for the treatment of sarcoidosis (already in Phase III) and low dose interleukin-6 (Atexakin Alfa) for the treatment of peripheral diabetic neuropathy (already in Phase II). Aviptadil development in sarcoidosis focuses the drug on an orphan disease market, in which European regulators have indicated that a single pivotal Phase III trial would be sufficient to support approval. Atexakin Alfa is in Phase II and has been the subject of multiple clinical trials. Based on its unique mechanism of action, Atexakin Alfa could become the first regenerative therapeutic for peripheral neuropathy.
 

Management board & Supervisory board

CEO
-
Management board
Jack Weinstein, Anthony Kim, J. Paul Waymack, Jan-Jaap Scherpbier, Jeremy Meinen, Marco Marotta, Nermeen Varawalla, Paolo Galfetti
Supervisory board
Dr. Raghuram Selvaraju, Paolo Galfetti, Patrice P. Jean, Tom Plitz
 

Company data

Name: RELIEF THERAPEUTICS Holding AG
Address: Avenue de Sécheron 15,CH-1202 Genève
Phone: +41-44-7235959
Fax: -
E-mail: contact@relieftherapeutics.com
Internet: www.relieftherapeutics.com/
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 44.53%
IPO date: -

Investor relations

Name: Michael Miller
IR phone: +1-917-633-6086
IR Fax: +41-44-7269012
IR e-mail: mmiller@rxir.com

Main Shareholders

GEM Global Yield Fund LLC SCS
 
51.38%
Freefloat
 
44.53%
Yves Sagot
 
4.09%